Robert L. Fine
Impact in
Papers in
- Oncology 75
- Drug Transport and Resistance Mechanisms 22
- Pancreatic and Hepatic Oncology Research 20
- Cancer-related Molecular Pathways 12
- Cancer Treatment and Pharmacology 10
- Co-authors
- Bruce A. Chabner (7 shared papers)Elizabeth R. Gerstner (1 shared paper)Alok A. Khorana (1 shared paper)Clifford Sachs (8 shared papers)Jeffrey N. Bruce (14 shared papers)Jitendra Patel (2 shared papers)John A. Chabot (16 shared papers)Jonathan Strosberg (1 shared paper)
- Journals
- Journal of Clinical Oncology (21 papers)Journal of Biological Chemistry (8 papers)Cancer Chemotherapy and Pharmacology (7 papers)Biochemical Pharmacology (7 papers)Cancer (6 papers)
- Partner nations
- United StatesUnited KingdomMalaysia
In The Last Decade
Robert L. Fine
121 papers receiving 6.0k citations
Robert L. Fine's Hit Papers
Peers
Comparison fields: 5 of 131
- Oncology 3.1k
- Genetics 646
- Neurology 833
- Cancer Research 688
- Epidemiology 1.3k
Countries citing papers authored by Robert L. Fine
This map shows the geographic impact of Robert L. Fine's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert L. Fine with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert L. Fine more than expected).
Fields of papers citing papers by Robert L. Fine
This network shows the impact of papers produced by Robert L. Fine. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert L. Fine. The network helps show where Robert L. Fine may publish in the future.
Co-authors
The 25 scholars most cited alongside Robert L. Fine, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 122 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas Hit paper breakdown → | 2010 | 519 |
| 2 | 1988 | 213 | |
| 3 | 2007 | 198 | |
| 4 | 2004 | 194 | |
| 5 | 2013 | 186 | |
| 6 | 1992 | 186 | |
| 7 | 1987 | 179 | |
| 8 | Frequent loss of heterozygosity on 6q at the mannose 6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors. | 1995 | 165 |
| 9 | 1993 | 155 | |
| 10 | 1996 | 154 | |
| 11 | 2010 | 152 | |
| 12 | 1986 | 120 | |
| 13 | 2011 | 117 | |
| 14 | 1994 | 105 | |
| 15 | 1999 | 95 | |
| 16 | 1995 | 87 | |
| 17 | 1996 | 82 | |
| 18 | 2000 | 82 | |
| 19 | 1996 | 81 | |
| 20 | 2001 | 80 |
About Robert L. Fine
Robert L. Fine is a scholar working on Oncology, Molecular Biology, Cancer Research, Epidemiology and Genetics, having authored 122 papers that have together received 6.1k indexed citations. Recurring topics across this work include Drug Transport and Resistance Mechanisms (22 papers), Pancreatic and Hepatic Oncology Research (20 papers), Cancer Genomics and Diagnostics (16 papers), Glioma Diagnosis and Treatment (15 papers), Neuroendocrine Tumor Research Advances (13 papers), Cancer-related Molecular Pathways (12 papers), Cancer Treatment and Pharmacology (10 papers) and HIV/AIDS drug development and treatment (10 papers). The work is most often cited by research in Oncology (3.1k citations), Genetics (646 citations), Neurology (833 citations), Cancer Research (688 citations) and Epidemiology (1.3k citations). Robert L. Fine has collaborated with scholars based in United States, United Kingdom and Malaysia. Frequent co-authors include Bruce A. Chabner, Elizabeth R. Gerstner, Alok A. Khorana, Clifford Sachs, Jeffrey N. Bruce, Jitendra Patel, John A. Chabot, Jonathan Strosberg, Junsung Choi and Aejaz Nasir. Their work appears in journals such as Journal of Clinical Oncology, Journal of Biological Chemistry, Cancer Chemotherapy and Pharmacology, Biochemical Pharmacology and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.